Lenalidomide Sandoz (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos. This action reduces angiogenesis, modulates immune cell activity, and directly inhibits tumor cell growth.

The dose of Lenalidomide Sandoz is individualized by the prescribing physician based on the specific indication, disease stage, renal function, and patient tolerance. Only a qualified healthcare professional should determine the appropriate regimen.

Lenalidomide Sandoz is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide Sandoz belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, which can be advantageous for outpatient management, and is often combined with dexamethasone or other agents for synergistic effect.

Store Lenalidomide Sandoz tablets at ambient temperature, below 25 °C. Keep the product in its original container, protect it from moisture, heat and direct sunlight to maintain potency throughout its shelf life.

Lenalidomide Sandoz is taken orally, usually once daily, with or without food, as directed by the treating physician. The tablets should be swallowed whole with water and not crushed or chewed unless otherwise instructed.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia leading to infection, and the potential for secondary malignancies. Patients should be monitored closely for signs of these complications.

Lenalidomide Sandoz should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled infections or severe renal impairment without appropriate dose adjustments.